282 related articles for article (PubMed ID: 19131041)
1. Toxic effects of dopamine metabolism in Parkinson's disease.
Hattoria N; Wanga M; Taka H; Fujimura T; Yoritaka A; Kubo S; Mochizuki H
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S35-8. PubMed ID: 19131041
[TBL] [Abstract][Full Text] [Related]
2. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Galvin JE
Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
[TBL] [Abstract][Full Text] [Related]
3. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Kostrzewa RM; Kostrzewa JP; Brus R
Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathogenesis of Parkinson's disease.
Gandhi S; Wood NW
Hum Mol Genet; 2005 Sep; 14(18):2749-55. PubMed ID: 16126732
[TBL] [Abstract][Full Text] [Related]
6. Alpha-synuclein and Parkinson's disease: a proteomic view.
Fasano M; Lopiano L
Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
[TBL] [Abstract][Full Text] [Related]
7. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress.
Mytilineou C; Walker RH; JnoBaptiste R; Olanow CW
J Pharmacol Exp Ther; 2003 Feb; 304(2):792-800. PubMed ID: 12538835
[TBL] [Abstract][Full Text] [Related]
8. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
[TBL] [Abstract][Full Text] [Related]
9. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
Maguire-Zeiss KA; Short DW; Federoff HJ
Brain Res Mol Brain Res; 2005 Mar; 134(1):18-23. PubMed ID: 15790526
[TBL] [Abstract][Full Text] [Related]
10. [Free radicals and ailing proteins--the culprits behind Parkinson disease?].
Smith R; Lotharius J; Brundin P
Lakartidningen; 2003 Apr; 100(15):1324-6, 1329-30. PubMed ID: 12739402
[TBL] [Abstract][Full Text] [Related]
11. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2012 Nov; 53(9):1791-806. PubMed ID: 22967820
[TBL] [Abstract][Full Text] [Related]
12. Protective and toxic roles of dopamine in Parkinson's disease.
Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
[TBL] [Abstract][Full Text] [Related]
13. [The role of JNK pathway in familial Parkinson's disease].
Jankowski M
Postepy Biochem; 2007; 53(3):297-303. PubMed ID: 18399358
[TBL] [Abstract][Full Text] [Related]
14. A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease.
Sass MB; Lorenz AN; Green RL; Coleman RA
J Neurosci Methods; 2009 Apr; 178(2):366-77. PubMed ID: 19136028
[TBL] [Abstract][Full Text] [Related]
15. alpha-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease.
Witt SN; Flower TR
FEMS Yeast Res; 2006 Dec; 6(8):1107-16. PubMed ID: 17156009
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease. Dopamine may sustain toxic protein.
Couzin J
Science; 2001 Nov; 294(5545):1257-8. PubMed ID: 11701896
[No Abstract] [Full Text] [Related]
17. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease.
Ahlskog JE
Mov Disord; 2005 Mar; 20(3):271-82. PubMed ID: 15580550
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
Hald A; Lotharius J
Exp Neurol; 2005 Jun; 193(2):279-90. PubMed ID: 15869932
[TBL] [Abstract][Full Text] [Related]
19. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis.
Henchcliffe C; Beal MF
Nat Clin Pract Neurol; 2008 Nov; 4(11):600-9. PubMed ID: 18978800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
